keyword
MENU ▼
Read by QxMD icon Read
search

Plaque psoriasis

keyword
https://www.readbyqxmd.com/read/29349534/psoriasis-from-pathogenesis-to-targeted-therapies
#1
REVIEW
Curdin Conrad, Michel Gilliet
Over the last decade, the management of psoriasis has witnessed a paradigm shift. Thanks to the increasing knowledge about the pathogenesis of psoriasis, targeted treatments with monoclonal antibodies have been developed. These antibodies, which target the pathogenic TNF/IL-23/IL-17-pathway, were shown to be safe and efficacious in the management of most patients with moderate to severe chronic plaque psoriasis. Recently, molecular and genetic studies in pustular and erythrodermic psoriasis have identified additional inflammatory pathways, providing evidence that psoriasis is a heterogeneous disease and highlighting the requirement for personalized disease characterization for treatment optimization...
January 18, 2018: Clinical Reviews in Allergy & Immunology
https://www.readbyqxmd.com/read/29349514/nb-uvb-irradiation-downregulates-keratin-17-expression-in-keratinocytes-by-inhibiting-the-erk1-2-and-stat3-signaling-pathways
#2
Yuchen Zhuang, Changxu Han, Bing Li, Liang Jin, Erle Dang, Hui Fang, Hongjiang Qiao, Gang Wang
Keratin-17 (K17) is a cytoskeletal protein produced by keratinocytes (KCs), which is overexpressed in psoriasis and may play a pivotal role in its pathogenesis. Narrow-band ultraviolet B (NB-UVB) irradiation is used as a general treatment for psoriasis, although its impact on K17 expression has yet to be determined. In this study, we aimed to investigate the effect of NB-UVB irradiation on K17 expression and its signaling pathways. After exposure to NB-UVB irradiation, immortalized human keratinocytes (HaCaT cells) were analyzed by flow cytometry, CCK-8 assays and transmission electron microscopy to examine proliferation...
January 18, 2018: Archives of Dermatological Research
https://www.readbyqxmd.com/read/29346172/apremilast-use-in-a-case-of-cicatricial-ectropion-secondary-to-severe-lamellar-ichthyosis
#3
Jean-Paul J Abboud, Alexander Whittington, Masih Ahmed, Jesse T Himebaugh, Lee A Wiley, Ahmad Haffar, John Nguyen
Ichthyosis is a cutaneous disorder characterized by excessive amounts of dry thickened skin surface scales. Ocular manifestations of ichthyosis include cicatricial ectropion, which may cause exposure keratoconjunctivitis and rarely corneal perforation. Topical emollients, anti-inflammatory ointments, and systemic retinoids have been used to control the disease process, while surgical correction with donor graft has been reserved for severe cases involving corneal exposure. The authors report a case of a Caucasian male with lamellar ichthyosis with severe bilateral upper and lower eyelid cicatricial ectropion and corneal ulceration requiring surgical correction...
January 17, 2018: Ophthalmic Plastic and Reconstructive Surgery
https://www.readbyqxmd.com/read/29344327/secukinumab-a-review-of-the-anti-il-17a-biologic-for-the-treatment-of-psoriasis
#4
REVIEW
Jillian Frieder, Dario Kivelevitch, Alan Menter
Psoriasis is a systemic inflammatory disease associated with numerous comorbidities and a profound impact on patients' quality of life. While its complex immune pathogenesis is still not fully delineated, current evidence supports a fundamental role of the T-helper-17 (TH-17) pathway and its related interleukin-17 (IL-17) cytokine. Thus, new antipsoriatic therapies have been developed to block this key cytokine and its downstream effects. Secukinumab is a fully humanized, monoclonal anti-IL-17A antibody, and the first in its class to be approved by the US Food and Drug Administration for the treatment of moderate to severe plaque psoriasis...
January 2018: Therapeutic Advances in Chronic Disease
https://www.readbyqxmd.com/read/29341446/carboxytherapy-for-treatment-of-localized-chronic-plaque-psoriasis-clinical-and-histopathologic-evaluation
#5
Abeer Mostafa Kamel, Rania Abdelghani
BACKGROUND: Multiple treatment options are introduced in treatment of chronic localized plaque psoriasis but with poor adherence and poor patients' satisfaction resulting in poor treatment outcome. OBJECTIVE: In this pilot study, we investigated the safety and efficacy of carboxytherapy in treatment of chronic localized plaque psoriasis. METHODS: Thirty adult patients with chronic localized plaque psoriasis were enrolled in this study. The patients received carboxytherapy injection once/week for 8 weeks...
January 17, 2018: Journal of Cosmetic Dermatology
https://www.readbyqxmd.com/read/29341192/population-pharmacokinetic-modeling-of-guselkumab-a-human-igg1%C3%AE-monoclonal-antibody-targeting-il-23-in-patients-with-moderate-to-severe-plaque-psoriasis
#6
Zhenling Yao, Chuanpu Hu, Yaowei Zhu, Zhenhua Xu, Bruce Randazzo, Yasmine Wasfi, Yang Chen, Amarnath Sharma, Honghui Zhou
Psoriasis is a common inflammatory skin disorder that requires chronic treatment and is associated with multiple comorbidities. Guselkumab, a human immunoglobulin-G1-lambda monoclonal antibody, binds to interleukin-23 with high specificity and affinity and is effective in treating moderate to severe plaque psoriasis. As part of the guselkumab psoriasis clinical trial program, using a confirmatory approach, a population pharmacokinetics (PopPK) model was established using 13 014 PK samples from 1454 guselkumab-treated patients across 3 phase 2/3 trials...
January 17, 2018: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29336190/a-cost-effectiveness-analysis-of-calcipotriol-plus-betamethasone-dipropionate-aerosol-foam-versus-gel-for-the-topical-treatment-of-plaque-psoriasis
#7
Peter Foley, Sinead Garrett, Lasse Ryttig
BACKGROUND: Calcipotriol 50 µg/g and betamethasone 0.5 mg/g dipropionate (Cal/BD) aerosol foam formulation provides greater effectiveness and improved patient preference compared with traditional Cal/BD formulations for the topical treatment of plaque psoriasis. OBJECTIVE: To determine the cost-effectiveness of Cal/BD foam compared with Cal/BD gel from the Australian perspective. METHODS: A Markov model was developed to evaluate the cost-effectiveness of topical Cal/BD foam and gel for the treatment of people with plaque psoriasis...
January 16, 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29334270/secukinumab-in-multi-failure-psoriatic-patients-the-last-hope
#8
M Magnano, C Loi, A Patrizi, P Sgubbi, R Balestri, G Rech, L Tasin, C R Girardelli, A Conti, G Odorici, A Campanati, A M Offidani, F Bardazzi
Psoriasis is a multi-systemic chronic inflammatory disease that affects about 1.5-3% of the general population, of which almost 20% suffer from a moderate-severe form. Those patients can be treated with a systemic agent, and, in case of scarce response or contraindications, they may require a biologic therapy, such as tumor necrosis factor or interleukin-12/23 inhibitors. When also those agents fail, clinicians face a true therapeutic challenge. We report a case series of multi-failure 16 patients, successfully treated with secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin-17A, recently approved for the treatment of plaque psoriasis, psoriatic arthritis and ankylosing spondylitis...
January 15, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/29318579/evaluation-of-icam-1-expression-and-vascular-changes-in-the-skin-of-patients-with-plaque-pustular-and-erythrodermic-psoriasis
#9
Aline L Bressan, Bruna L S Picciani, Luna Azulay-Abulafia, Anna K Fausto-Silva, Paula N Almeida, Karin S G Cunha, Eliane P Dias, Sueli Carneiro
BACKGROUND: Psoriasis is a chronic inflammatory disease. Pustular, erythrodermic, and extensive plaque psoriasis are responsible for systemic complications. Systemic capillary leak syndrome is the complication with greater progression to death and occurs due to vascular changes. PURPOSE: The aim of this study was to evaluate vascular changes through the expression of CD34 and ICAM-1 in plaque, pustular, and erythrodermic psoriasis. METHODS: The sample consisted of seven patients with erythrodermic psoriasis, 24 with moderate-severe plaque psoriasis, 14 with mild plaque psoriasis and 13 with pustular psoriasis...
January 10, 2018: International Journal of Dermatology
https://www.readbyqxmd.com/read/29315555/autoimmunity-and-autoimmune-comorbidities-in-psoriasis
#10
REVIEW
Kazuhisa Furue, Takamichi Ito, Gaku Tsuji, Takafumi Kadono, Takeshi Nakahara, Masutaka Furue
Psoriasis is characterized by widespread scaly erythematous plaques that cause significant physical and psychological burdens for the affected individuals. Accelerated inflammation driven by the TNF-α/IL-23/IL-17 axis is now known to be the major mechanism of the development of psoriasis. In addition, psoriasis has an autoimmune nature that manifests as autoreactive T cells and is comorbid with other autoimmune diseases, such as autoimmune bullous diseases, vitiligo, alopecia and thyroiditis. In this article, we review the recent topics on autoimmunity and autoimmune comorbidities in psoriasis...
January 9, 2018: Immunology
https://www.readbyqxmd.com/read/29304933/comparison-of-adalimumab-and-etanercept-for-the-treatment-of-moderate-to-severe-psoriasis-an-indirect-comparison-using-individual-patient-data-from-randomized-trials
#11
Kim A Papp, Min Yang, Murali Sundaram, John Jarvis, Keith A Betts, Yanjun Bao, James E Signorovitch
OBJECTIVES: To compare outcomes between adalimumab and etanercept in the treatment of moderate to severe plaque psoriasis. METHODS: Study groups included patients randomized to adalimumab or placebo (REVEAL and CHAMPION trials) and those randomized to etanercept or placebo (M10-114 and M10-315 trials). Week 12 outcomes were compared between patients receiving adalimumab and those receiving etanercept after adjusting for cross-trial differences in patient characteristics using propensity score weighting and after subtracting effects of placebo...
January 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29299628/-vitiligo-and-psoriasis-an-underdiagnosed-coincidence
#12
A-K Dumke, P Elsner, S Goetze
We report the case of a 59-year-old woman who simultaneously suffered from psoriasis and vitiligo. The depigmented areas were predominantly but not exclusively limited to current or former psoriatic plaques. These two diseases share many common features, e. g., both are T‑cell-mediated autoimmune diseases in which the Koebner phenomenon occurs. However, it is still not known whether the coincidence is random or significant. Prospective clinical and epidemiological research will hopefully reveal the association soon...
January 3, 2018: Der Hautarzt; Zeitschrift Für Dermatologie, Venerologie, und Verwandte Gebiete
https://www.readbyqxmd.com/read/29297664/contemporary-management-of-moderate-to-severe-plaque-psoriasis
#13
Jashin J Wu
Psoriasis is a multisystem inflammatory disease that is often underdiagnosed, leaving many patients untreated. Plaque psoriasis, the most common form of the disease, affects approximately 80% to 90% of patients with psoriasis. Formulating a treatment plan can be complicated when various factors are considered. For example, type of therapy is dependent on the severity of the disease. Topical agents are preferred for mild disease, while phototherapy alone or in combination with systemic agents is recommended for the treatment of moderate to severe plaque psoriasis...
December 2017: American Journal of Managed Care
https://www.readbyqxmd.com/read/29290125/management-of-common-side-effects-of-apremilast
#14
Annie Langley, Jennifer Beecker
Apremilast is a relatively new therapy for the treatment of moderate to severe plaque psoriasis in adults. While this medication is considered safe with a very low risk of serious side effects, a few common (≥5% of patients) mild to moderate side effects have been reported, including diarrhea, nausea, headache, and nasopharyngitis. Not addressing these symptoms may lead to medication nonadherence and unnecessary discontinuation of therapy. These side effects are often easily managed with interventions available to the practicing dermatologist, and in only rare instances will these side effects require dose adjustment or discontinuation of therapy...
December 1, 2017: Journal of Cutaneous Medicine and Surgery
https://www.readbyqxmd.com/read/29286164/differential-effects-of-wnt5a-on-the-proliferation-differentiation-and-inflammatory-response-of-keratinocytes
#15
Wenming Wang, Xiaoling Yu, Chao Wu, Hongzhong Jin
The predominant role of Wnt family member 5A (Wnt5a) is to induce non-canonical Wnt signalling pathways, including the Wnt‑Ca2+ and Wnt‑planar cell polarity pathways. Enhanced Wnt5a expression is involved in the formation of psoriatic plaques; however, its mechanistic role remains to be determined. In the present study, the effects of Wnt5a expression on HaCaT keratinocytes were investigated. HaCaT cells were cultured in medium supplemented with 0, 40 or 80 ng/ml Wnt5a for 24 h. Cell proliferation, the cell cycle, gene expression and inflammatory responses were investigated using Cell‑Counting Kit‑8 assays, flow cytometry analyses, reverse transcription‑quantitative polymerase chain reaction analyses and enzyme‑linked immunosorbent assays, respectively...
December 27, 2017: Molecular Medicine Reports
https://www.readbyqxmd.com/read/29279330/microrna-146-and-cell-trauma-downregulate-expression-of-the-psoriasis-associated-atypical-chemokine-receptor-ackr2
#16
Kave Shams, Mariola Kurowska-Stolarska, Fabian Schütte, A David Burden, Clive S McKimmie, Gerard J Graham
Chemokines are the principal regulators of leukocyte migration and are essential for initiation and maintenance of inflammation. Atypical chemokine receptor 2 (ACKR2) binds and scavenges proinflammatory CC-chemokines, regulates cutaneous T-cell positioning, and limits the spread of inflammation in vivo. Altered ACKR2 function has been implicated in several inflammatory disorders, including psoriasis, a common and debilitating T cell-driven disorder characterized by thick erythematous skin plaques. ACKR2 expression is abnormal in psoriatic skin, with decreased expression correlating with recruitment of T cells into the epidermis and increased inflammation...
December 26, 2017: Journal of Biological Chemistry
https://www.readbyqxmd.com/read/29273799/rna-seq-identifies-a-diminished-differentiation-gene-signature-in-primary-monolayer-keratinocytes-grown-from-lesional-and-uninvolved-psoriatic-skin
#17
William R Swindell, Mrinal K Sarkar, Yun Liang, Xianying Xing, Jaymie Baliwag, James T Elder, Andrew Johnston, Nicole L Ward, Johann E Gudjonsson
Keratinocyte (KC) hyper-proliferation and epidermal thickening are characteristic features of psoriasis lesions, but the specific contributions of KCs to plaque formation are not fully understood. This study used RNA-seq to investigate the transcriptome of primary monolayer KC cultures grown from lesional (PP) and non-lesional (PN) biopsies of psoriasis patients and control subjects (NN). Whole skin biopsies from the same subjects were evaluated concurrently. RNA-seq analysis of whole skin identified a larger number of psoriasis-increased differentially expressed genes (DEGs), but analysis of KC cultures identified more PP- and PN-decreased DEGs...
December 22, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29249124/histopathological-aspects-of-psoriasis-and-its-uncommon-variants
#18
Caterina Ferreli, Anna L Pinna, Luca Pilloni, Carlo F Tomasini, Franco Rongioletti
Psoriasis is a chronic complex multisystem, inflammatory, skin disorder that causes vasodilatation and hyperproliferation of keratinocytes, whose clinical expression includes a thickened, erythematous skin, often covered with silver grey scales. Psoriasis is a unique disease where both autoimmune and autoinflammatory responses coexist and the balance between the two components is essential in determining its clinical and histopathological presentation. Adaptive immune responses prevail in chronic plaque psoriasis while innate and autoinflammatory responses predominate in pustular psoriasis...
December 15, 2017: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
https://www.readbyqxmd.com/read/29249053/a-review-of-switching-biologic-agents-in-the-treatment-of-moderate-to-severe-plaque-psoriasis
#19
REVIEW
Yifan Hu, Zeyu Chen, Yu Gong, Yuling Shi
Psoriasis is an immune-mediated polygenic inherited skin disease. Many biologic agents have been approved for the treatment of moderate-to-severe plaque psoriasis. The most commonly utilized biologics include TNF-α antagonists (etanercept, infliximab, and adalimumab), IL-12/23P40 antagonist (ustekinumab), IL-23P19 antagonist (guselkumab), IL-17A antagonist (secukinumab and ixekizumab), and IL-17RA antagonist (brodalumab). However, some patients may fail to respond well to their first biologic agent. Reasons for failure include primary failure (lack of initial efficacy), secondary failure (loss of efficacy over time) or the development of adverse effects...
December 16, 2017: Clinical Drug Investigation
https://www.readbyqxmd.com/read/29247500/biologic-treatment-sequences-for-plaque-psoriasis-a-cost-utility-analysis-based-on-10-years-of-dutch-real-world-evidence-from-biocapture
#20
S L Klijn, J M P A van den Reek, G van de Wetering, A van der Kolk, E M G J de Jong, W Kievit
BACKGROUND: Treatment with biologics may be indicated for patients with moderate to severe plaque psoriasis, but comparative evidence on cost-effectiveness is limited. Switching of biologics is common, but it is unclear what the effect is of differences in sequences of biologics. OBJECTIVE: Evaluate the cost-effectiveness of different biologic treatment sequences for psoriasis based on real-world evidence. METHODS: A sequence model was developed to evaluate the costs and health effects of three consecutive lines of biologic treatments (for example adalimumab-etanercept-ustekinumab versus etanercept-ustekinumab-adalimumab) over a 10-year time horizon in the Netherlands...
December 16, 2017: British Journal of Dermatology
keyword
keyword
82378
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"